Profound Medical Corp. Innovates BPH Treatment with TULSA-PRO and TULSA-AI Technology
- Profound Medical's TULSA-PRO® system offers a minimally invasive treatment for benign prostatic hyperplasia (BPH) using thermal ultrasound ablation.
- The TULSA-AI technology enhances precision in BPH treatments, providing personalized care and improving patient outcomes.
- Profound Medical is positioned as a leader in urology innovation, with multiple regulatory approvals for its TULSA-PRO system.
Profound Medical Corp. Leads Innovation in BPH Treatment with TULSA-PRO System
Profound Medical Corporation achieves a significant milestone in the treatment of benign prostatic hyperplasia (BPH) with the successful commercial use of its TULSA-PRO® system, enhanced by the innovative TULSA-AI® technology. This first treatment, performed by Dr. Naveen Kella at The Urology Place on June 10, 2025, represents a transformative approach to managing BPH, a condition that affects millions of men globally. The TULSA-PRO system employs thermal ultrasound ablation to reduce prostate volume, offering a minimally invasive solution that preserves surrounding tissue and minimizes typical side effects associated with traditional BPH treatments.
The TULSA-AI module significantly enhances the precision and efficiency of the procedure. By providing tailored treatment plans based on individual patient anatomy, it marks a departure from conventional methods that often lack personalization. Traditional interventions, such as transurethral resection of the prostate (TURP), have remained largely unchanged for decades, leading to high rates of discontinuation among patients. In contrast, the TULSA procedure, which can be completed within 60 to 90 minutes, allows for real-time MRI guidance to precisely eliminate obstructive prostate tissue, thereby preserving urinary function and sexual health. This advancement not only improves patient outcomes but also positions Profound Medical at the forefront of innovation in urology.
As the demand for effective BPH therapies increases, particularly among the aging population, Profound Medical's commitment to advancing healthcare solutions through cutting-edge technology is underscored by this achievement. The successful rollout of the TULSA-PRO system with TULSA-AI solidifies the company's leadership in image-guided therapies and reflects its mission to address the unmet needs of patients suffering from BPH. With the procedure being CE marked, Health Canada approved, and having received FDA 510(k) clearance, Profound Medical is poised to make a significant impact in the urology market and cater to the growing awareness of men's health issues.
In addition to the BPH treatment, Profound Medical is also advancing its Sonalleve® technology, which has received CE marking for treating uterine fibroids and has been approved in China. Furthermore, the device has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The company is actively exploring additional applications for Sonalleve, indicating a robust pipeline of innovations aimed at enhancing patient care across various medical conditions.